Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383229 | 0.90 | HRH3 (0.39) | HRH3 | |
| SCHEMBL4387644 | 0.90 | HRH3 (0.34) | HRH3ALDH1A1 | |
| SCHEMBL7656144 | 0.81 | HRH3 (0.33) | HRH3ALDH1A1 | |
| SCHEMBL4388569 | 0.78 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL4382877 | 0.72 | KMT2A (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4382878 | 0.72 | KMT2A (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4543147 | 0.72 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL4543149 | 0.72 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL1446118 | 0.71 | KMT2A (0.42) | MEN1KMT2AALDH1A1 | |
| SCHEMBL27344018 | 0.67 | MEN1 (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2002085861-A1 | IMIDAZOLIDINE COMPOUNDS AND THEIR USE AS CXCR3 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6469002-B1 | COMPOUNDS WHICH MODULATE CHEMOKINE RECEPTOR ACTIVITY AND ARE USEFUL IN TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885MEN1 3396/4885KMT2A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.